Floatz logo

Evomela

HLA-A*0201 Positive Cells Present

Jonsson Comprehensive Cancer CenterPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the HLA-A*0201 Positive Cells Present cohort.

Asset / SponsorPhaseRating
Cmvpp65-A*0201 Peptide Vaccine
City of Hope Medical Center
Phase 2B
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 1/2CCC
cd8-positive t-lymphocyte
M.D. Anderson Cancer Center
Phase 1/2CCC
Utomilumab
M.D. Anderson Cancer Center
Phase 1/2CCC
wt1-sensitized allogeneic t-lymphocytes
Fred Hutchinson Cancer Center
Phase 1/2CCC

View all 12 →

Same molecule, other indications

Evomela is also rated in:

diffuse large B-cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BBB
Indicative ·
76 / 100
View asset →
myeloproliferative neoplasmDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →